Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations
| Autor: | Snitker, Soren, Doerfler, Rebecca M., Soliman, Elsayed Z., Deo, Rajat, St. Peter, Wendy L., Kramlik, Susan, Fischer, Michael J., Navaneethan, Sankar, Delafontaine, Patrice, Jaar, Bernard G., Ojo, Akinlolu, Makos, Gail K., Slaven, Anne, Weir, Matthew R., Zhan, Min, Fink, Jeffrey C. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Epidemiology 030232 urology & nephrology Amiodarone 030204 cardiovascular system & hematology Citalopram Critical Care and Intensive Care Medicine QT interval Diabetes Complications 03 medical and health sciences chemistry.chemical_compound Electrocardiography 0302 clinical medicine Furosemide Heart Rate Metolazone Fluoxetine Heart rate medicine Humans Renal Insufficiency Chronic Diuretics Aged Transplantation medicine.diagnostic_test business.industry Venlafaxine Hydrochloride Heart Proton Pump Inhibitors Original Articles Middle Aged chemistry Nephrology Anesthesia Hydroxyzine Spironolactone Histamine H1 Antagonists Antidepressive Agents Second-Generation Female Electrical conduction system of the heart business Anti-Arrhythmia Agents medicine.drug |
| Popis: | Background and objectives Several drugs used in CKD can prolong electrocardiographic conduction. We examined the use of electrocardiogram QT-prolonging medications in predialysis CKD and their association with QT duration. Design, setting, participants, & measurements In total, 3252 Chronic Renal Insufficiency Cohort participants with at least one study electrocardiogram between 2003 and 2011 were included. QT-prolonging medications used in 100 or more visits (n=16,451 visits) along with diuretics and proton pump inhibitors, given their potential for electrolyte disturbances, were examined for QT interval prolongation. Results Mean QT interval corrected for heart rate was at 414±21 (±SD) milliseconds and prolonged (≥450 milliseconds) in 4.6% of electrocardiograms. QT interval corrected for heart rate was inversely related to serum potassium and calcium. Medications classified as QT prolonging were taken at 76% of visits, with two or more of these taken at 33% of visits. Of 30 medications examined, eight were associated with statistically significant QT interval corrected for heart rate prolongation after adjustment for comorbidities, potassium, and calcium, including amiodarone (+10±2 milliseconds), metolazone (+7±2 milliseconds), fluoxetine (+4±1 milliseconds), citalopram (+4±1 milliseconds), hydroxyzine (+4±1 milliseconds), escitalopram (+3±2 milliseconds), venlafaxine (+3±1 milliseconds), and furosemide (+3±0 milliseconds). Potassium-depleting diuretics were associated with minimal decrements in potassium (between 0.1 and 0.3 mEq/L) and smaller changes in calcium. Diuretics associated with a change in QT interval corrected for heart rate before adjustment for potassium and calcium were metolazone (+8±3 milliseconds), furosemide (+4±1 milliseconds), and spironolactone (−3±3 milliseconds). Most of the QT prolongation associated with metolazone and furosemide, but not spironolactone, remained after adjustment for potassium and calcium. Proton pump inhibitors were not associated with QT prolongation. Conclusions Use of medications associated with QT prolongation is common in CKD; the safety implications of these findings should be considered in these high-risk patients. Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_08_09_CJASNPodcast_17_09_b.mp3 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|